Table 2.
Primary and Secondary Outcomes.
| Total (n = 39) | |||
|---|---|---|---|
| Outcomes, n (%) | |||
| Hospital admission | 13 (33) | ||
| Death | 5 (13) | ||
| IV infiltration | 0 (0) | ||
| Allergic reaction | 0 (0) | ||
| Adverse effects, n (%) | |||
| Creatinine increase >0.3 mg/dL | 1 (3) | ||
| AST >2× ULN | 1 (3) | ||
| ALT >2× ULN | 6 (15) | ||
| Total bilirubin >2× ULN | 0 | ||
| Baseline lab values, median (IQR) | Before (n = 36) | After (n = 36) | p-value* |
| Creatinine (mg/dL) | 0.93 (0.85-1.05) | 0.89 (0.77-0.97) | .006 |
| AST (U/L) | 35 (29-40) | 25 (22-42) | .06 |
| ALT (U/L) | 29 (24-48) | 36 (26-56) | .07 |
| Total bilirubin (mg/dL) | 0.4 (0.3-0.5) | 0.5 (0.3-0.6) | .05 |
Lab data was only available for 36 of 39 patients in the cohort. Before lab values were recorded from blood drawn on the first day of remdesivir. After values were those recorded on the last day of therapy.
*
Reported for Wilcoxon Signed-Rank test.